Please assess the completion status of the following clinical trial:

Trial Title: A Single-Arm Pilot Study With Low-Dose Rituximab Plus Standard Oral Prednisone In Idiopathic Autoimmune Hemolytic Anemia

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Newly diagnosed warm or cold AIHA, defined by symptomatic anemia and positive DAT, in the absence of underlying lymphoproliferative, infectious or neoplastic disease (according to the single Center diagnostic criteria).~* Idiopathic warm or cold AIHA relapsed after first line treatment with oral prednisone.~* Aged \>18 years~* ECOG performance status grade 0, 1 or 2~* No psychiatric illness that precludes understanding concepts of the trial or signing informed consent~* Patients who have provided written informed consent prior to study participation, with the understanding that the consent may be withdrawn by the patient at any time without prejudice.~Exclusion Criteria:~* Cell or humoral immunologic deficit (congenital or acquired)~* Any other co-existing medical or psychological condition that would preclude participation in the study or compromise ability to give informed consent~* Active bacterial, viral, or fungal infection requiring systemic therapy HIV or HbsAg positive (with HBV-DNA+) or HCV-Ab positive (with HCV-RNA+) patients~* History of malignancies within 3 years prior to study entry~* Concomitant immunosuppressive or cytotoxic treatment~* Positive pregnancy test. Lactation.~* The presence of associated organ-specific autoimmune diseases do not constitute exclusion criteria. Previous splenectomy does not constitute exclusion criteria

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).